Name: GW-501516(Cardarine) 100x10mg
Brand: Averlane Labs
Price: 60.00 EUR
Availability: InStock

NOT FOR HUMAN CONSUMPTION

Cardarine (GW501516), also known as Endurobol. is a high-affinity PPARβ/δ agonist developed in the 1990s for dyslipidemia, metabolic syndrome, and cardiovascular risk reduction. PPARδ activation remodels skeletal muscle, liver, adipose tissue, and macrophages toward fatty-acid oxidation (FAO), mitochondrial biogenesis (PGC-1α), and anti-inflammatory profiles. Development was halted after rodent carcinogenicity signals in long-term toxicology studies. GW501516 is not FDA/EMA approved, and all PPARδ agonists are prohibited by WADA.

Additional Benefits of GW501516 Now Under Investigation

Benefit	Key take-aways
1 Endurance enhancement & metabolic reprogramming	Strong upregulation of CPT-1, PDK4, UCP3, and oxidative myofiber gene sets; greatly improved time-to-exhaustion in rodents, an “exercise mimetic” phenotype. <br/>Cell Metabolism; Nature Medicine
2 Lipid optimization	Marked TG ↓, VLDL ↓, HDL ↑, improved apoA-I dynamics, and reduced foam-cell formation, mechanistically attractive for atherosclerosis. <br/>ATVB; Circulation Research
3 Insulin sensitivity & glucose homeostasis	Better HOMA-IR, increased muscle FAO, reduced hepatic steatosis, enhanced glucose uptake under insulin stimulation. <br/>Diabetes; JCI
4 Liver protection (NAFLD/MASH)	Decreases hepatic fat, downregulates lipogenesis (SREBP-1c) and inflammation/fibrosis signals (TNF-α, TGF-β). <br/>Hepatology; Gastroenterology
5 Cardiovascular & endothelial benefits	↑ eNOS/NO, ↓ VCAM-1/ICAM-1, improves vascular relaxation, reduces atherosclerotic area in hyperlipidemic models. <br/>Circulation; Cardiovascular Research
6 Anti-inflammatory & immune modulation	Represses NF-κB/AP-1 cytokine cascades; shifts macrophages away from inflammatory phenotype; improves colitis indicators. <br/>PNAS; Gut
7 Renal & pulmonary protection	Reduces fibrosis and oxidative injury in ischemia-reperfusion kidney injury, and mitigates pulmonary hypertension/remodeling in PAH models. <br/>Kidney Int; AJP Lung
8 Neuroprotection & cognitive signals	Improves mitochondrial efficiency and reduces microglial inflammation; modest benefits in toxin/aging models. <br/>Neurobiology of Aging; Glia
9 Metabolic flexibility under caloric load	Enhances lipid oxidation during fasting/exercise and preserves glycaemic stability, attractive for metabolic-syndrome models. <br/>Cell Reports; Metabolism

2. Molecular Mechanism of Action

2.1 Receptor pharmacodynamics

PPARβ/δ agonist → heterodimerizes with RXR → binds PPRE → induces FAO, mitochondrial, and oxidative-gene expression.
FAO/mitochondrial genes: PGC-1α, CPT-1, ACOX1, UCP3, PDK4.
Anti-inflammatory effects: Transrepression of NF-κB/AP-1, reducing cytokines and adhesion molecules.
Macrophage lipid handling: ↑ ABCA1/ABCG1 → cholesterol efflux; ↓ foam-cell formation.

2.2 Down-stream biology

Pathway	Functional outcome	Context
PGC-1α–FAO program	↑ fatty-acid oxidation, ↑ endurance	Skeletal muscle
ABCA1/ABCG1	Cholesterol efflux, anti-atherogenic	Macrophages
NF-κB/AP-1 restraint	↓ cytokines/inflammation	Vascular & immune
eNOS activation	↑ NO, endothelial function	CV system
Anti-fibrotic (TGF-β)	↓ collagen deposition	Liver/kidney/lung

3. Pharmacokinetics (preclinical & early clinical)

Route: Oral.
Half-life: Estimated 12–24 h in animals; human PK poorly published.
Absorption: Good oral bioavailability; highly lipophilic.
Distribution: Wide tissue distribution with liver and muscle enrichment.
Metabolism: Hepatic oxidative metabolism (CYP-mediated, details unpublished).

4. Evidence Summary

Metabolic disease: Strong rodent evidence for insulin sensitization, glucose-tolerance improvement, and NAFLD reduction.
CV disease: Reduced atherosclerosis and improved endothelial health.
Exercise physiology: Profound endurance gains in rodents via metabolic gene reprogramming.
Human trials: Only short Phase 1 safety studies; no efficacy trials completed.

Evidence quality note: Extensive animal and mechanistic literature but no validated human efficacy. Long-term rodent carcinogenicity at high exposures halted development.

5. Emerging Clinical Interests (conceptual)

Field	Rationale	Status
Metabolic syndrome/T2D	FAO + insulin sensitivity ↑	Concept/preclinical
NAFLD/MASH	Lipid handling + anti-inflammatory	Preclinical
Atherosclerosis/CVD prevention	Efflux + endothelial support	Preclinical
PAH/fibrosis	Anti-remodeling	Preclinical
IBD/colitis	Immune modulation	Preclinical
Neurodegeneration	Mitochondrial support	Preclinical

6. Safety & Tolerability

6.1 Known/observed

Short-term (human Phase 1): Generally well tolerated, mild headache, nausea, or URI-like symptoms.
Metabolic effects: Beneficial lipids/glucose signals in animals; unknown long-term human impact.

6.2 Major concern: rodent carcinogenicity

Long-term GLP toxicology in multiple species showed rapid, high-incidence tumor formation across various tissues at pharma-scale exposures.
Mechanism unclear; may relate to PPARδ’s proliferative roles in some tissues.

6.3 Additional risks (theoretical/observed)

Carcinogenesis via β-catenin/TGF-β interactions (class concern).
Cardiac hypertrophy/arrhythmia signals absent in rodents but insufficiently studied in humans.
Hepatic drift at high doses.
Sport/anti-doping: Strictly prohibited by WADA (metabolic modulators).

Comparative matrix (class)

Feature	GW501516	GW0742	Fenofibrate (PPARα)
Target	PPARδ	PPARδ	PPARα
Human approval	None	None	Yes (lipids)
Carcinogenicity	Strong rodent signal	Unknown	No δ-class signal
Metabolic effects	Strong	Strong	Moderate

7. Regulatory Landscape

Not approved by FDA/EMA/PMDA.
Development discontinued due to oncogenicity in animals.
Remains a research-only compound.
All PPARδ agonists = WADA prohibited.

8. Practical Take & Future Directions

No human self-use. Safety window unknown; serious carcinogenicity concerns.
Research directions:
- Biased PPARδ agonists that retain FAO/mitochondrial benefits while reducing proliferative risk.
- Tissue-targeted δ agonists (e.g., muscle-selective) to avoid systemic exposure.
- Combination with GLP-1/GIP agonists or AMPK activators for metabolic synergy if safety improved.
Trial considerations (hypothetical): Require low-dose, short exposure, intense oncologic monitoring, and biomarker-driven go/no-go gating.

Selected References

Cell Metabolism; Nature Medicine, PPARδ-driven endurance and metabolic remodeling.
ATVB; Circulation Research; Cardiovascular Research, Lipid and atheroprotective effects; endothelial function.
Diabetes; JCI, Insulin-sensitizing and NAFLD improvements.
Hepatology; Gastroenterology, Anti-steatotic/anti-inflammatory liver results.
PNAS; Gut, Immune/NF-κB transrepression and colitis relief.
Kidney International; AJP Lung, Kidney/lung fibrosis and remodeling.
GLP toxicology datasets summarizing carcinogenicity outcomes (industry/EMA briefing notes).

GW-501516(Cardarine) 100x10mg

Complete the setup